Use of bDNA testing in the immunologically nonresponding patient who has a low or undetectable viral load by RT-PCR testing

HIV Clinical Trials

Volumn 4, Issue 2, 2003, Pages 92-98

  Grimes, Richard M ^a   Lewis, Stanley T ^b   Visnegarwala, Fehmida ^c   Goodly, Joseph ^b   Sutton, Richard ^c   Rodriguez Barradas, Maria ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

bDNA testing; Clades; HIV 1 viral load; RT PCR testing

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; DNA B; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLADISTICS; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 0037354545     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/V4NV-2Q1T-DNQP-8X03     Document Type: Article

References (19)

1. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis. 2001;183:1328-1335.
2. Meyers R, Szuch W, Nerurkar V, Alexander S, Patel J, Joseph J. The impact of HIV-1 diversity in Maryland: under quantifying "non-B" subtype HIV-1 viral loads with the FDA approved assay. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000; San Francisco CA. Abstract 173.
3. Parekh B, Phillips S, Granade TC, Baggs J, Hu DJ, Respess R. Impact of HIV viral subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses. 1999;15:133-142.
4. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. February 5, 2001. Available at: www.hivatis.org
5. Walter EA, Gilliam B, Delmar JA, et al. Clinical implications of identifying non-B subtypes of human immunodeficiency virus type 1 infection. Clin Infect Dis. 2002;31(3):798-802.
6. Zapiola I, Fernandez Giuliano S, Wainstein C, et al. Misquantification of plasma HIV-RNA subtype F among clinical samples from Argentina. In: Program and abstracts of the XIIIth International AIDS Conference; July 9-14, 2000. Durban, South Africa. Abstract MoPeA2128.
7. Triques K, Coste J, Perret JL, et al. Efficiencies of four versions of the Amplicor HIV-1 Monitor test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol. 1999;37:110-116.
8. Elbeik T, Alvord WG, Trichavaroj R, et al. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor Version 1.5. JAIDS. 2002;29:330-339.
9. Balotta C, Facchi G, Violin M, et al. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. JAIDS. 2001;27:499-505.
10. Russell KL, Carcamo A, Watts, DM, et al. Emerging genetic diversity of HIV-1 in South America. AIDS. 2000;1:1785-1791.
11. Fonjungo PN, Mpoudi EN, Torimiro JN, et al. Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. AIDS Res Hum Retroviruses. 2000;16:1319-1324.
12. Holguin A, Rodes B, Soriano V, Gonsalez-Lahoz J. Recombinant HIV-1 variants circulating in Spain. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco CA. Abstract 175.
13. Grabar S, Le Moing V, Goujard C, et al, Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after six months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-410.
14. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953.
15. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4 cell count in HIV-1 infected individuals remaining viraemic with highly active antiretrovirals. Lancet. 1998;351:723-724.
16. Beatrice ST, Collie M, El-Fishawy M, Oleszko WR. Detection of large numbers of HIV-1 group M non-B subtypes in New York City. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco CA. Abstract 171.
17. Zaid I, Weinstock H, Parekh B, et al. Surveillance of HIV-1 subtypes in the United States, 1998-present. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco CA. Abstract 215.
18. Womack C, Roth W, Newman C, et al. Identification of non-B human immunodeficiency virus type 1 subtypes in rural Georgia. J Infect Dis. 2001;183:138-142.
19. Dwyer DE, Herring B, Wang AL, et al. Multiple HIV-1 subtypes circulating in Australia. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco CA. Abstract 177.